Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 1/20 | 0.46 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.46 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.45 |
| ▸ | KIT | P10721 | 1/20 | 0.45 |
| ▸ | PIK3C3 | Q8NEB9 | 8/20 | 0.44 |
| ▸ | IL2 | P60568 | 1/20 | 0.43 |
| ▸ | EDNRB | P24530 | 2/20 | 0.43 |
| ▸ | EDNRA | P25101 | 2/20 | 0.43 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5033851 | 0.92 | SGK1 (0.48) | PIK3CDPIK3CGKITPIK3C3IL2 | |
| SCHEMBL5029428 | 0.88 | PIK3CA (0.45) | RORCPIK3CDPIK3CAKITPIK3C3 | |
| SCHEMBL8233270 | 0.87 | PIK3CD (0.45) | PIK3CDPIK3CGPIK3CAIL2EDNRB | |
| SCHEMBL5029404 | 0.85 | IL2 (0.49) | PIK3CDPIK3CGPIK3C3IL2EDNRB | |
| SCHEMBL5029678 | 0.84 | IL2 (0.51) | PIK3CDPIK3CGIL2EDNRBEDNRA | |
| SCHEMBL14377329 | 0.83 | PIK3CD (0.44) | PIK3CDPIK3CGPIK3CAPIK3C3IL2 | |
| SCHEMBL5029384 | 0.80 | ALDH1A1 (0.47) | PIK3CDPIK3CGIL2EDNRBEDNRA | |
| SCHEMBL5027347 | 0.80 | RORC (0.51) | RORCPIK3CAKITPIK3C3EDNRB | |
| SCHEMBL5029416 | 0.80 | KDM4E (0.48) | KITPIK3C3 | |
| SCHEMBL2843847 | 0.78 | ALDH1A1 (0.52) | IL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | claimed |
| EP-1983971-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | Synta Pharmaceuticals Corporation (US) | 2008-10-29 | — | — | EP | claimed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | claimed |
| WO-2007087441-A2 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2007-08-02 | — | — | WO | claimed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741960-B2 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2014-06-03 | — | — | US | disclosed |
| EP-1973910-A1 | PYRROLO Ý3,2-C¨PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-10-01 | — | — | EP | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | SYNTA PHARMACEUTICALS CORP. (US) | 2007-10-25 | — | — | US | disclosed |
| WO-2007085188-A1 | PYRROLO [3,2-C] PYRIDINE-4-ONE 2-INDOLINONE PROTEIN KINASE INHIBITORS | SHANGHAI HENGRUI PHARMACEUTICAL CO. LTD. (CN) | 2007-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249050-A1 | Substituted aromatic compounds for inflammation and immune-related uses | CCR1, NLRP1, NLRP3 | RORC 59/4885PIK3CD 3936/4885PIK3CG 3957/4885 |
| US-20140242120-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CCR1, NLRP1, NLRP3 | RORC 59/4885PIK3CD 3936/4885PIK3CG 3957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.